[HLBANK] YoY Annualized Quarter Result on 31-Mar-2020 [#3]

Announcement Date
29-May-2020
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2020
Quarter
31-Mar-2020 [#3]
Profit Trend
QoQ- -7.69%
YoY- -5.07%
View:
Show?
Annualized Quarter Result
31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 CAGR
Revenue 5,843,129 5,465,350 5,512,776 4,775,602 4,744,014 4,884,334 4,531,641 4.32%
PBT 4,781,673 4,199,296 3,528,437 3,120,953 3,270,654 3,291,489 2,757,724 9.60%
Tax -843,648 -1,023,772 -633,560 -554,044 -566,576 -608,729 -541,592 7.66%
NP 3,938,025 3,175,524 2,894,877 2,566,909 2,704,078 2,682,760 2,216,132 10.05%
-
NP to SH 3,938,025 3,175,524 2,894,877 2,566,909 2,704,078 2,682,760 2,216,132 10.05%
-
Tax Rate 17.64% 24.38% 17.96% 17.75% 17.32% 18.49% 19.64% -
Total Cost 1,905,104 2,289,826 2,617,898 2,208,693 2,039,936 2,201,574 2,315,509 -3.19%
-
Net Worth 32,922,045 30,351,463 28,539,430 26,360,066 24,898,371 23,340,592 22,091,076 6.87%
Dividend
31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 CAGR
Div 600,941 491,521 403,455 436,605 436,454 436,400 409,094 6.61%
Div Payout % 15.26% 15.48% 13.94% 17.01% 16.14% 16.27% 18.46% -
Equity
31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 CAGR
Net Worth 32,922,045 30,351,463 28,539,430 26,360,066 24,898,371 23,340,592 22,091,076 6.87%
NOSH 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 0.00%
Ratio Analysis
31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 CAGR
NP Margin 67.40% 58.10% 52.51% 53.75% 57.00% 54.93% 48.90% -
ROE 11.96% 10.46% 10.14% 9.74% 10.86% 11.49% 10.03% -
Per Share
31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 CAGR
RPS 285.22 266.86 269.27 233.34 231.88 238.77 221.55 4.29%
EPS 192.23 155.05 141.40 125.43 132.17 131.15 108.35 10.02%
DPS 29.33 24.00 19.71 21.33 21.33 21.33 20.00 6.58%
NAPS 16.07 14.82 13.94 12.88 12.17 11.41 10.80 6.84%
Adjusted Per Share Value based on latest NOSH - 2,167,718
31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 CAGR
RPS 285.04 266.61 268.92 232.96 231.42 238.27 221.06 4.32%
EPS 192.10 154.91 141.22 125.22 131.91 130.87 108.11 10.05%
DPS 29.32 23.98 19.68 21.30 21.29 21.29 19.96 6.61%
NAPS 16.06 14.806 13.9221 12.8589 12.1459 11.386 10.7764 6.87%
Price Multiplier on Financial Quarter End Date
31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 CAGR
Date 31/03/23 31/03/22 31/03/21 31/03/20 29/03/19 30/03/18 31/03/17 -
Price 20.22 20.20 18.70 13.46 20.30 18.80 13.76 -
P/RPS 7.09 7.57 6.94 5.77 8.75 7.87 6.21 2.23%
P/EPS 10.52 13.03 13.22 10.73 15.36 14.34 12.70 -3.08%
EY 9.51 7.68 7.56 9.32 6.51 6.98 7.87 3.20%
DY 1.45 1.19 1.05 1.58 1.05 1.13 1.45 0.00%
P/NAPS 1.26 1.36 1.34 1.05 1.67 1.65 1.27 -0.13%
Price Multiplier on Announcement Date
31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 CAGR
Date 31/05/23 30/05/22 27/05/21 29/05/20 28/05/19 30/05/18 29/05/17 -
Price 19.54 21.12 17.90 13.66 18.94 18.60 13.96 -
P/RPS 6.85 7.91 6.65 5.85 8.17 7.79 6.30 1.40%
P/EPS 10.17 13.62 12.66 10.89 14.33 14.18 12.88 -3.85%
EY 9.84 7.34 7.90 9.18 6.98 7.05 7.76 4.03%
DY 1.50 1.14 1.10 1.56 1.13 1.15 1.43 0.79%
P/NAPS 1.22 1.43 1.28 1.06 1.56 1.63 1.29 -0.92%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment